Anixa Biosciences, Inc. (NASDAQ:ANIX) has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its novel ovarian cancer vaccine technology. The patent, titled 'Ovarian Cancer Vaccines,' covers nucleic acid-based delivery of the vaccine. The technology is being developed in partnership with Cleveland Clinic. Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute (NCI).